Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study to Evaluate the Safety and Efficacy of IM83 CAR-T Cells for the Treatment of Relapsed or Refractory Osteosarcoma

NCT06412458 is registered in ClinicalTrials.gov with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor.

NCT NCT06412458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06412458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study to Evaluate the Safety and Efficacy of IM83 CAR-T Cells for the Treatment of Relapsed or Refractory Osteosarcoma
Lead sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
June 15, 2024
Completion date
June 15, 2026
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent osteosarcoma, refractory osteosarcoma